Market by Product Type, Gender, Application, End-user, and Country Outlook | Forecast 2023-2030
As per Triton Market Research’s report, the botulinum toxin market in Europe is expected to obtain a growth rate of 10.20% during the forecast period 2023-2030.
Report scope can be customized per your requirements - Request Free Sample Report
The
countries studied in the region consist of:
•
United Kingdom
•
Germany
•
France
•
Spain
•
Italy
• Poland
•
Rest of Europe
Nonsurgical procedures are becoming increasingly
popular across various European countries. This trend is driven by rising
consumer demand and a streamlined approval process from the European Medicines
Agency that allows for sales throughout the region. Several players have been
expanding their collaborations to enhance technical capabilities. Concurrently,
global corporations are directing their efforts toward introducing innovations
in the region’s market. These factors are thus expected to open novel
opportunities for the botulinum toxin market.
Germany
secures the majority of share in the botulinum toxin market. There has been a notable increase in the
popularity of cosmetic surgeries within the country aimed at enhancing an
individual’s physical appearance. The expertise of German specialists and the
latest technological advancements has yielded significant outcomes, driving a
substantial demand for cosmetic procedures. Besides, the nation is positioned
for robust growth in botulinum toxin treatments, owing to growing public
awareness, an aging populace, and a growing inclination towards aesthetic
enhancements.
On the other hand, the advancements in
healthcare systems are expected to elevate the demand for cosmetic procedures
in the United Kingdom. In this regard, healthcare provisions have influenced
various product launches. Moreover, several players are concentrating on
innovation for advanced patient outcomes, which is anticipated to propel the
growth of the botulinum toxin market.
Botulinum toxin type A injections are one of the
most extensively utilized cosmetic treatments for addressing facial wrinkles,
commonly referred to as facial lines. Noteworthy examples of these injections
include Botox, Dysport, Xeomin, and Jeuveau. Furthermore, this toxin addresses
diverse medical ailments like muscle spasms and migraines. The market is sectioned into product type, application, gender, and
end-user. The product type is further bifurcated into type A and B
botulinum toxin.
The
renowned companies in the market consist of Galderma SA, Lanzhou Institute of
Biological Products Co Ltd, Daewoong Pharmaceutical Co Ltd, Ipsen Pharma, Hugel
Inc, and Candela Medical Corporation.
Galderma SA, headquartered in Zug, Switzerland,
is a pharmaceutical firm specializing in dermatology treatments and skincare
products. Its range caters to various skin conditions like acne, rosacea,
psoriasis, and other conditions influenced by steroids, fungal nail infections,
pigmentary issues, skin cancer, and skin aging. The company markets its
offerings through recognizable brand names, such as Aklief, Epiduo, Epidio
Forte, etc.
Key deliverables of the report:
●
Market CAGR during the forecasting years 2023-2030
●
Detailed data highlighting key insights, industry components, and
market strategies
●
Comprehensive information and estimation of the botulinum toxin
market revenue growth in Europe and its influence on the parent market
●
In-depth study of forthcoming trends in consumer behavioral
patterns
●
A meticulous analysis of the competitive landscape, vendor
scorecard, and Porter’s Five Forces
●
A wide-ranging study of factors that will challenge the Europe
botulinum toxin market’s growth during the upcoming years
Want to get specific insights? Our team of analysts
can customize this report based on your preferences. Connect with us here.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. EUROPE
BOTULINUM TOXIN MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. IMPACT
ANALYSIS ON THE BOTULINUM TOXIN MARKET
2.1.1. COVID-19
IMPACT
2.2. KEY
INSIGHTS
2.2.1. GROWING
DEMAND FOR NON-INVASIVE COSMETIC PROCEDURES
2.2.2. SURGE
IN DEMAND FOR BOTULINUM TOXIN AMONG MILLENNIALS
AND
GEN-Z
2.3. PORTER’S
FIVE FORCES ANALYSIS
2.3.1. THREAT
OF NEW ENTRANTS
2.3.2. THREAT
OF SUBSTITUTES
2.3.3. BARGAINING
POWER OF BUYERS
2.3.4. BARGAINING
POWER OF SUPPLIERS
2.3.5. THREAT
OF COMPETITIVE RIVALRY
2.4. REGULATORY
FRAMEWORK
2.5. KEY
MARKET STRATEGIES
2.5.1. PRODUCT
LAUNCHES
2.5.2. COLLABORATIONS
2.5.3. BUSINESS
EXPANSIONS & DIVESTITURES
2.5.4. ACQUISITIONS
2.6. MARKET
DRIVERS
2.6.1. SURGE
IN DEMAND FOR AESTHETIC PROCEDURES
2.6.2. RISE
IN GERIATRIC POPULATION
2.7. MARKET
CHALLENGES
2.7.1. LIMITED
REIMBURSEMENT POLICIES SUPPORTING COSMETIC PROCEDURES
2.7.2. ADVERSE
EFFECTS OF BOTULINUM TOXIN
2.7.3. EMERGING
PROBLEM OF BOTULINUM TOXIN TYPE A RESISTANCE
2.8. MARKET
OPPORTUNITIES
2.8.1. EXPANSION
OF BOTULINUM TOXIN INTO THERAPEUTIC APPLICATIONS
2.8.2. RISING
MEDICAL TOURISM
2.9. ANALYST
PERSPECTIVE
3. EUROPE
BOTULINUM TOXIN MARKET OUTLOOK - BY PRODUCT TYPE
3.1. TYPE A
BOTULINUM TOXIN
3.2. TYPE B
BOTULINUM TOXIN
4. EUROPE
BOTULINUM TOXIN MARKET OUTLOOK - BY GENDER
4.1. WOMEN
4.2. MEN
5. EUROPE
BOTULINUM TOXIN MARKET OUTLOOK - BY APPLICATION
5.1. AESTHETIC
5.1.1. CROW’S
FEET
5.1.2. FOREHEAD
LINES
5.1.3. FROWN
LINES/GLABELLAR
5.1.4. SQUARE
JAW/MASSETER
5.1.5. OTHER
AESTHETIC APPLICATIONS
5.2. MEDICAL
5.2.1. CHRONIC
MIGRAINE
5.2.2. MUSCLE
SPASM
5.2.3. OVERACTIVE
BLADDER
5.2.4. HYPERHIDROSIS
5.2.5. OTHER
MEDICAL APPLICATIONS
6. EUROPE
BOTULINUM TOXIN MARKET OUTLOOK - BY END-USER
6.1. SPECIALTY
AND DERMATOLOGY CLINICS
6.2. HOSPITALS
AND CLINICS
6.3. OTHER
END-USERS
7. EUROPE
BOTULINUM TOXIN MARKET – BY COUNTRY OUTLOOK
7.1. EUROPE
7.1.1. MARKET
BY PRODUCT TYPE
7.1.2. MARKET
BY GENDER
7.1.3. MARKET
BY APPLICATION
7.1.3.1. MARKET
BY AESTHETIC
7.1.3.2. MARKET
BY MEDICAL
7.1.4. MARKET
BY END-USER
7.1.5. COUNTRY
ANALYSIS
7.1.5.1. UNITED
KINGDOM
7.1.5.1.1. UNITED
KINGDOM BOTULINUM TOXIN MARKET FORECAST & PROSPECTS
7.1.5.2. GERMANY
7.1.5.2.1. GERMANY
BOTULINUM TOXIN MARKET FORECAST & PROSPECTS
7.1.5.3. FRANCE
7.1.5.3.1. FRANCE
BOTULINUM TOXIN MARKET FORECAST & PROSPECTS
7.1.5.4. ITALY
7.1.5.4.1. ITALY
BOTULINUM TOXIN MARKET FORECAST & PROSPECTS
7.1.5.5. SPAIN
7.1.5.5.1. SPAIN
BOTULINUM TOXIN MARKET FORECAST & PROSPECTS
7.1.5.6. POLAND
7.1.5.6.1. POLAND
BOTULINUM TOXIN MARKET FORECAST & PROSPECTS
7.1.5.7. REST
OF EUROPE
7.1.5.7.1. REST
OF EUROPE BOTULINUM TOXIN MARKET FORECAST & PROSPECTS
8. COMPETITIVE
LANDSCAPE
8.1. ABBVIE
INC
8.1.1. OVERVIEW
8.1.2. PRODUCT
PORTFOLIO
8.1.3. KEY
STRENGTHS
8.1.4. KEY
CHALLENGES
8.2. EVOLUS
INC
8.2.1. OVERVIEW
8.2.2. PRODUCT
PORTFOLIO
8.2.3. KEY
STRENGTHS
8.2.4. KEY
CHALLENGES
8.3. MEDYTOX
INC
8.3.1. OVERVIEW
8.3.2. PRODUCT
PORTFOLIO
8.3.3. KEY
STRENGTHS
8.3.4. KEY
CHALLENGES
8.4. LANZHOU
INSTITUTE OF BIOLOGICAL PRODUCTS CO LTD
8.4.1. OVERVIEW
8.4.2. PRODUCT
PORTFOLIO
8.4.3. KEY
STRENGTHS
8.4.4. KEY
CHALLENGES
8.5. DAEWOONG
PHARMACEUTICAL CO LTD
8.5.1. OVERVIEW
8.5.2. PRODUCT
PORTFOLIO
8.5.3. KEY
STRENGTHS
8.5.4. KEY
CHALLENGES
8.6. GALDERMA
SA
8.6.1. OVERVIEW
8.6.2. PRODUCT
PORTFOLIO
8.6.3. KEY
STRENGTHS
8.6.4. KEY
CHALLENGES
8.7. IPSEN
PHARMA
8.7.1. OVERVIEW
8.7.2. PRODUCT
PORTFOLIO
8.7.3. KEY
STRENGTHS
8.7.4. KEY
CHALLENGES
8.8. HUGEL
INC
8.8.1. OVERVIEW
8.8.2. PRODUCT
PORTFOLIO
8.8.3. KEY
STRENGTHS
8.8.4. KEY
CHALLENGES
8.9. CANDELA
MEDICAL CORPORATION
8.9.1. OVERVIEW
8.9.2. PRODUCT
PORTFOLIO
8.9.3. KEY
STRENGTHS
8.9.4. KEY
CHALLENGES
8.10. MERZ
PHARMA GMBH & CO KGAA
8.10.1. OVERVIEW
8.10.2. PRODUCT
PORTFOLIO
8.10.3. KEY
STRENGTHS
8.10.4. KEY
CHALLENGES
8.11. REVANCE
THERAPEUTICS INC
8.11.1. OVERVIEW
8.11.2. PRODUCT
PORTFOLIO
8.12. US
WORLDMEDS LLC
8.12.1. OVERVIEW
8.12.2. PRODUCT
PORTFOLIO
9. RESEARCH
METHODOLOGY & SCOPE
9.1. RESEARCH
SCOPE & DELIVERABLES
9.2. SOURCES
OF DATA
9.3. RESEARCH
METHODOLOGY
TABLE 1: EUROPE BOTULINUM
TOXIN MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)
TABLE 2: EUROPE REGULATORY
FRAMEWORK FOR BOTULINUM TOXIN
TABLE 3: LIST OF PRODUCT
LAUNCHES
TABLE 4: LIST OF
COLLABORATIONS
TABLE 5: LIST OF BUSINESS
EXPANSIONS & DIVESTITURES
TABLE 6: LIST OF ACQUISITIONS
TABLE 7: EXAMPLE OF
COMMERCIALLY AVAILABLE BOTULINUM TOXIN TYPE A FOR AESTHETIC PROCEDURES
TABLE 8: EUROPE BOTULINUM
TOXIN MARKET, BY PRODUCT TYPE, 2023-2030 (IN $ MILLION)
TABLE 9: EUROPE BOTULINUM
TOXIN MARKET, BY GENDER, 2023-2030 (IN $ MILLION)
TABLE 10: EUROPE BOTULINUM
TOXIN MARKET, BY APPLICATION, 2023-2030 (IN $ MILLION)
TABLE 11: EUROPE BOTULINUM
TOXIN MARKET, BY AESTHETIC, 2023-2030 (IN $ MILLION)
TABLE 12: EUROPE BOTULINUM
TOXIN MARKET, BY MEDICAL, 2023-2030 (IN $ MILLION)
TABLE 13: EUROPE BOTULINUM
TOXIN MARKET, BY END-USER, 2023-2030 (IN $ MILLION)
TABLE 14: EUROPE BOTULINUM
TOXIN MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)
FIGURE 1: EUROPE BOTULINUM
TOXIN MARKET, BY PRODUCT TYPE, 2022 & 2030 (IN %)
FIGURE 2: EUROPE BOTULINUM
TOXIN MARKET, BY TYPE A BOTULINUM TOXIN, 2023-2030 (IN $ MILLION)
FIGURE 3: EUROPE BOTULINUM
TOXIN MARKET, BY TYPE B BOTULINUM TOXIN, 2023-2030 (IN $ MILLION)
FIGURE 4: EUROPE BOTULINUM
TOXIN MARKET, BY GENDER, 2022 & 2030 (IN %)
FIGURE 5: EUROPE BOTULINUM
TOXIN MARKET, BY WOMEN, 2023-2030 (IN $ MILLION)
FIGURE 6: EUROPE BOTULINUM
TOXIN MARKET, BY MEN, 2023-2030 (IN $ MILLION)
FIGURE 7: EUROPE BOTULINUM
TOXIN MARKET, BY APPLICATION, 2022 & 2030 (IN %)
FIGURE 8: EUROPE BOTULINUM
TOXIN MARKET, BY AESTHETIC, 2023-2030 (IN $ MILLION)
FIGURE 9: EUROPE BOTULINUM
TOXIN MARKET, BY AESTHETIC, 2022 & 2030 (IN %)
FIGURE 10: EUROPE BOTULINUM
TOXIN MARKET, BY CROW’S FEET, 2023-2030 (IN $ MILLION)
FIGURE 11: EUROPE BOTULINUM
TOXIN MARKET, BY FOREHEAD LINES, 2023-2030 (IN $ MILLION)
FIGURE 12: EUROPE BOTULINUM
TOXIN MARKET, BY FROWN LINES/GLABELLAR, 2023-2030 (IN $ MILLION)
FIGURE 13: EUROPE BOTULINUM
TOXIN MARKET, BY SQUARE JAW/MASSETER, 2023-2030 (IN $ MILLION)
FIGURE 14: EUROPE BOTULINUM
TOXIN MARKET, BY OTHER AESTHETIC APPLICATIONS, 2023-2030 (IN $ MILLION)
FIGURE 15: EUROPE BOTULINUM
TOXIN MARKET, BY MEDICAL, 2023-2030 (IN $ MILLION)
FIGURE 16: EUROPE BOTULINUM
TOXIN MARKET, BY MEDICAL, 2022 & 2030 (IN %)
FIGURE 17: EUROPE BOTULINUM
TOXIN MARKET, BY CHRONIC MIGRAINE, 2023-2030 (IN $ MILLION)
FIGURE 18: EUROPE BOTULINUM
TOXIN MARKET, BY MUSCLE SPASM, 2023-2030 (IN $ MILLION)
FIGURE 19: EUROPE BOTULINUM
TOXIN MARKET, BY OVERACTIVE BLADDER, 2023-2030 (IN $ MILLION)
FIGURE 20: EUROPE BOTULINUM
TOXIN MARKET, BY HYPERHIDROSIS, 2023-2030 (IN $ MILLION)
FIGURE 21: EUROPE BOTULINUM
TOXIN MARKET, BY OTHER MEDICAL APPLICATIONS, 2023-2030 (IN $ MILLION)
FIGURE 22: EUROPE BOTULINUM
TOXIN MARKET, BY END-USER, 2022 & 2030 (IN %)
FIGURE 23: EUROPE BOTULINUM
TOXIN MARKET, BY SPECIALTY AND DERMATOLOGY CLINICS, 2023-2030 (IN $ MILLION)
FIGURE 24: EUROPE BOTULINUM
TOXIN MARKET, BY HOSPITALS AND CLINICS, 2023-2030 (IN $ MILLION)
FIGURE 25: EUROPE BOTULINUM
TOXIN MARKET, BY OTHER END-USERS, 2023-2030 (IN $ MILLION)
FIGURE 26: EUROPE BOTULINUM
TOXIN MARKET, BY COUNTRY OUTLOOK, 2022 & 2030 (IN %)
FIGURE 27: UNITED KINGDOM
BOTULINUM TOXIN MARKET 2023-2030 (IN $ MILLION)
FIGURE 28: GERMANY BOTULINUM
TOXIN MARKET 2023-2030 (IN $ MILLION)
FIGURE 29: FRANCE BOTULINUM
TOXIN MARKET 2023-2030 (IN $ MILLION)
FIGURE 30: ITALY BOTULINUM
TOXIN MARKET 2023-2030 (IN $ MILLION)
FIGURE 31: SPAIN BOTULINUM
TOXIN MARKET 2023-2030 (IN $ MILLION)
FIGURE 32: POLAND BOTULINUM
TOXIN MARKET 2023-2030 (IN $ MILLION)
FIGURE 33: REST OF EUROPE
BOTULINUM TOXIN MARKET 2023-2030 (IN $ MILLION)